Health
Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate – Press Release – Digital Journal
Joshua Liang, Chief Executive Officer of Clover Biopharmaceuticals, said, “We are excited to share these important preclinical results showing that our S-Trimer COVID-19 vaccine candidate induces immune protection against SARS-CoV-2, and we are also pleased w…
CHENGDU, China–(Business Wire)–Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, today announced positive preclinical data demonstrating that its protein-based COVID-19 S-Trimer vaccine candidate in combination with adjuvants from either GSK (London Stock Exchange: GSK) or Dynavax (Nasdaq: DVAX) induces a strong immune response and protection against SARS-CoV-2 in animal models. The man…
-
General22 hours agoQueensland government strikes new deal with Bravus to defer royalties, expand Carmichael coal mine
-
Noosa News22 hours agoHeartbreaking CCTV shows father and son moments before fatal crash in Regents Park, Queensland
-
Noosa News21 hours agoFamily’s heartbreak after Trevor Doyle found dead in park in Logan
-
General21 hours agoTwo men involved in fatal helicopter accident charged over stealing crocodile eggs from Kakadu National Park